Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of first‐line chemotherapy: A multicenter prospective cohort study

Bevacizumab is the first antiangiogenetic monoclonal antibody, combined with platinum‐based double agent chemotherapy, which has been reported to improve the objective response rate (ORR) and progression‐free survival (PFS) in patients with advanced nonsquamous non‐small cell lung cancer (NSCLC), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ai, Bin, Zhang, Li, Huang, Dingzhi, Chen, Jun, Liu, Zhe, Hu, Xingsheng, Zhou, Shengyu, Hu, Yi, Zhao, Jun, Yang, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705615/
https://www.ncbi.nlm.nih.gov/pubmed/33073527
http://dx.doi.org/10.1111/1759-7714.13687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705615/
https://www.ncbi.nlm.nih.gov/pubmed/33073527
http://dx.doi.org/10.1111/1759-7714.13687

Ejemplares similares